Get started

Pharaceuticals

ZOM a love child to novice investorsZOM is interesting since through out the pandemic, people wanted to find ways to make money at home. That's why we had stories from Hertz, DOGE, GME, AMC, and more, but some of these investors found r/PennyStocks. I could list alot of hot names like NNDM, IDEX, XSPA, and more, but we are here to talk about ZOM yet its good to know what kind of investors are in/attractive to a stock like ZOM. Overall I'm a mid term bear, but you could be neutral. News: Now I haven't invested a single penny, yet I like seeing a stock that had an mc over 2billion dollars just to come back to pennystock land of the dead -3 insiders sale publish on Apr 13. -Apr 15: ZOM releases a Investor news on their website stating their distributor failed to help them gain initial sales, so in return they are going to go with a direct sales approach. Also in the letter they couldn't state when they will be profitable. This is a red flag on multiparts. First: they push their own problems on a distributor and not their product. There still hasn't been any demand from the stock price if their product was successful. Second: Changing gears on how to market their device, since launch and haven't tweeted/remain inactive on social media like twitter since Jan 4th is very concerning on if they are still trying to build this company. Third: Profitability. Again we don't know the demand and we don't know if this new marketing strategy will work. This means the company will continue its cash burn and sale shares or dilute share holders until profitability. -Earnings are coming up, but it should be clear they will miss Other News: -ZOM releases their product early causing the swing traders to be off guard and start the "sale the news" -Twitter inactive since Jan 4 -Whole market (besides crypto) has been crashing since the start of this year TA: I know the news section was scary and some things are opinionated, but theres questions that need to be answered -Downtrend line since March 26, but sale off started on March 16. Leans Bearish -Resistance is at 1.00130, 1.4166, and then 2.0075. If the downtrend line holds up .9947 is resistance at open. Leans bearish -EMA continues down with 50 at roughly 1.06. 128 1.36, and 1.49 at the 200. Massive moves are needed, so unlikely to see it hitting there anytime soon. Would need sideways movement or a bounce back. -Support hits .8367, then a massive drop too 0.4413 since between was a gap up. After that its a drop too 0.2802 another unknownzone, but it lighter note could be a buying opportunity 0.2802-04413. This area would be massive pain since if you bought at ath you would be down over 70% and at 0.2802 its at 89% which is prime for a bounce back. Buying from .5-.28 should only be gamble money. -MACD leans bearish -RSI is way oversold with resistance at 51.91 -VPVR levels mean shit atm, but during the rally the last big one I see is at 0.488, so a quick trade from .5 buy in could bounce back to .8-$1 on a trading perspective. Final thoughts Now this stock has had major bearish news and the question is will the earnings help or cause more pain. The answer isn't clear cut, cause as an investor or a speculator we don't know the sales and the quick change in direction on sales cause me to believe in the short term and mid bearish perspective. Now if earnings come out and sales are better than suspected then theres no problems, but watch out if the next days after it continues too sale off.
AMEX:ZOMShort
by nathanielx9
4
$TEVA - Weekly Chart 2020Teva's earnings May 7th - www.sec.gov Weekly chart is flashing buy signals with the 50SMA Crossing back under the price. Unknowns: COVID-19 impact on TEVA earnings Decision - Wait until after earnings to get in, still to many unknowns. The reason I like TEVA : Possible Turn-around play, looking for teva to turn net-loss to net-profit in the coming years if they continue to lower debt and start turning profit. Earnings (loss) per share attributable to ordinary shareholders: Basic ($) 2020 - Lower? 2019 - (0.91) even lower? 2018 - (2.35) Lower loss 2017 - (16.26) Huge loss 2016 - 0.07 Smaller profit 2015 - 1.84 Profit Diluted ($) 2019 - (0.91) 2018 - (2.35) 2017 - (16.26) 2016 - 0.07 2015 -1.82 www.sec.gov
NYSE:TEVALong
by AaronX
Hikma Pharmaceuticals - Injecting some bullish momentum.Buy Hikma Pharmaceuticals (HIK.L) Hikma Pharmaceuticals PLC develops, manufactures, and markets pharmaceutical products. The Company offers branded and non-branded generic and in-licensed pharmaceutical products. Hikma Pharmaceuticals serves customers worldwide. Market Cap: £4.79Billion The long-term trend on Hikma remains bullish. The corrective move lower in recent weeks has found some support at the 38.2% Fibonacci level. The posting of a bullish engulfing candle while simultaneously breaking from a wedge pattern is bullish for short term sentiment. Further upside is expected from here, targeting the previous highs at 2345p from 15th March 2017. Stop: 1920p Target 1: 2210p Target 2: 2345p Target 3: 2400p Interested in UK Stocks? Join our free Telegram channel for up to date analysis on the best main market opportunities in the UK right now - t.me
LSE:HIKLong
by Investamate